Anti-HLA Hyperimmunization

Anti-HLA hyperimmunization means a person’s immune system has made very high levels of antibodies against other people’s HLA proteins (human leukocyte antigens). HLA proteins sit on cells and help the immune system tell “self” from “non-self.” When someone is “hyperimmunized,” their blood contains many anti-HLA antibodies that can strongly react to tissues, blood cells (like platelets), or an organ from another person. Because of this, organ offers are harder to match, platelet transfusions may not work well, and the risk of antibody-mediated rejection (AMR) is higher if transplantation proceeds without careful planning. In other words, they are highly sensitized. A widely used numeric summary of how sensitized a person is is the cPRA (calculated Panel Reactive Antibody) score: it estimates what percentage of potential donors would be incompatible due to the patient’s anti-HLA antibodies (higher cPRA = fewer compatible donors). OPTN+3Frontiers Publishing Partnerships+3OPTN+3

Anti-HLA hyperimmunization means a person has very high levels of antibodies against human leukocyte antigens (HLA). These antibodies usually form after exposure to another person’s tissues through pregnancy, blood transfusion, or a past transplant. When HLA antibodies are strong and broad, the immune system quickly attacks a new organ from a donor, causing a positive crossmatch and a high risk of antibody-mediated rejection (AMR). People with very high calculated panel reactive antibody (cPRA) often wait longer for a compatible organ, and they may need special matching or desensitization before transplant. Kidney International+2Lippincott Journals+2

Clinicians detect and monitor these antibodies with modern lab tests—especially Luminex single-antigen bead (SAB) assays—which can identify specific HLA targets and give a semi-quantitative signal (“MFI”) for how strongly serum binds to each HLA. Traditional CDC crossmatch and more sensitive flow cytometric crossmatch tests help determine whether antibodies in the recipient will bind to cells from a specific donor. Newer add-on tests check whether donor-specific antibodies (DSA) activate complement (e.g., C1q or C3d binding), which signals higher risk for rejection and graft loss. Frontiers Publishing Partnerships+7PMC+7Frontiers+7

Other names

You may see the same concept written as:

• Highly sensitized (or “sensitized”) transplant candidate

• Hyperimmunized patient

• High PRA or high cPRA patient

• Preformed anti-HLA antibodies (if present before transplant)

• Donor-specific antibodies (DSA) (if antibodies target a particular donor’s HLA) Frontiers Publishing Partnerships+1

Types

1. By timing

• Preformed (pre-existing) anti-HLA antibodies: present before the transplant—these cause immediate or early problems if the donor expresses those HLAs (risk of hyperacute or early AMR). Frontiers Publishing Partnerships

• De novo antibodies: develop after transplant; when they fix complement (C1q/C3d-positive), risk of chronic damage and graft loss rises. PMC+1

2. By HLA class

• Class I (A, B, C) antibodies and Class II (DR, DQ, DP) antibodies; class II DSA are strongly linked with chronic AMR. Frontiers

3. By functional risk

• Complement-binding DSA (C1q/C3d positive) = higher risk for AMR/graft failure.

• Non–complement-binding DSA = can still be risky, but generally lower risk than complement-binding. PMC+1

4. By breadth

• Broadly reactive (high cPRA) vs. narrowly reactive (few specificities). Broad reactivity severely limits compatible donors. OPTN

---

Causes

1. Previous organ transplant: exposure to donor HLA often triggers persistent anti-HLA antibodies. Frontiers Publishing Partnerships

2. Pregnancy: fetal HLA inherited from the father can sensitize the mother; more pregnancies increase risk. Frontiers Publishing Partnerships

3. Blood transfusions (especially non-leukodepleted in the past): leukocytes and platelet HLA can immunize recipients. PubMed

4. Platelet transfusions: platelets express HLA; repeated transfusions can produce anti-HLA and cause platelet refractoriness. (General immunohematology principle aligned with HLA literature.) Frontiers

5. Tissue grafts (e.g., skin, bone, corneal grafts) from other people: contain HLA and can sensitize. (Transplant immunology principle; see sensitization definitions.) Frontiers Publishing Partnerships

6. Use of HLA-bearing cellular therapies (e.g., some donor lymphocyte infusions): exposure to non-self HLA. Frontiers

7. Prior ventricular assist device (VAD) or mechanical circulatory support with transfusion exposure: often accompanied by multiple transfusions leading to sensitization. (Mechanism via transfusion exposure; widely discussed in transplant practice.) PubMed

8. Repeated miscarriage or fetal loss with fetomaternal HLA exposure: can generate anti-HLA. Frontiers Publishing Partnerships

9. Transfusion during surgery (e.g., cardiac, trauma): cumulative leukocyte/platelet HLA exposure. PubMed

10. Immunizations coupled with donor exposure (bystander activation): rarely, heightened immune activation may amplify responses to allo-HLA when exposure occurs near the same period. (Inferred immunology principle; baseline sensitization causes remain pregnancy/transfusion/transplant.) Frontiers Publishing Partnerships

11. Incomplete leukoreduction historically: older transfusion practices increased HLA sensitization risk. PubMed

12. Emergency non-matched platelet support: repeated HLA-unmatched platelets can sensitize. Frontiers

13. Prior graft failure with AMR: DSA often persist or broaden after antibody-mediated rejection. Frontiers Publishing Partnerships

14. Exposure via organ offers and positive crossmatches during evaluation (rare today due to virtual crossmatch): historic cause of sensitization. PMC

15. Transplant nephrectomy (after failed kidney) with ongoing inflammation can maintain/provoke antibody production. (Common transplant observation linked to persistent DSA risk in sensitized patients.) Frontiers Publishing Partnerships

16. Alloimmunization after solid organ + multiple transfusions during ICU stays. PubMed

17. HLA class II exposure via antigen-presenting cells in transfused products (B cells/monocytes). Frontiers

18. Repeated desensitization attempts with interim exposures (e.g., platelets) can sometimes maintain antibody pools if exposure continues. (Practice-based caution in hyperimmunized management.) PMC

19. Adjuvant immune activation (infections/inflammation) around an exposure may heighten allo-response. (Mechanistic immunology principle; clinical guidelines acknowledge inflammation increases risk.) Frontiers Publishing Partnerships

20. Shared epitope/“eplet” exposure across different donors or transfusions (epitope-focused sensitization): once primed, the immune system recognizes structurally similar HLA epitopes, broadening antibody patterns. (SAB/epitope literature context.) Xia & He Publishing

---

Symptoms

Important: Having anti-HLA antibodies by itself often causes no direct symptoms. Problems appear when the person receives an organ or platelet transfusion that the antibodies can attack.

1. Organ transplant rejection signs: fever, malaise, and graft tenderness or swelling. (General AMR presentation.) Frontiers Publishing Partnerships

2. Kidney graft problems: drop in urine output, rising creatinine, fluid retention, high blood pressure. Frontiers Publishing Partnerships

3. Heart graft problems: shortness of breath, fatigue, fluid overload; ECG/echo may show dysfunction. Wiley Online Library

4. Liver graft problems: abnormal liver tests, reduced bile flow, coagulopathy. (General transplant medicine.) Frontiers Publishing Partnerships

5. Lung graft problems: low oxygen levels, breathlessness; imaging shows perfusion mismatch. (General transplant medicine.) Frontiers Publishing Partnerships

6. Hyperacute rejection (rare now): minutes–hours post-reperfusion the organ becomes mottled and fails due to preformed DSA. Frontiers Publishing Partnerships

7. Early antibody-mediated rejection (AMR): days–weeks after transplant with DSA and graft dysfunction. Frontiers Publishing Partnerships

8. Chronic rejection/slow graft scarring: months–years later, often linked to persistent class II DSA. Frontiers Publishing Partnerships

9. Platelet refractoriness: after transfusion, platelet count barely rises; bleeding risk stays high because anti-HLA destroys transfused platelets. Frontiers

10. Transfusion reactions to incompatible platelets: chills/fever or poor increment rather than classic hemolysis. Frontiers

11. Delayed graft function (especially kidney): need for dialysis soon after transplant due to antibody injury. Frontiers Publishing Partnerships

12. Edema and sudden weight gain: fluid retention when a kidney graft is not filtering well. Frontiers Publishing Partnerships

13. Hypertension escalation: a sign of kidney graft dysfunction. Frontiers Publishing Partnerships

14. Reduced exercise tolerance (heart/lung graft injury). Wiley Online Library

15. Anxiety and prolonged waiting time for a compatible organ: a real life impact of high cPRA. OPTN

---

Diagnostic tests

A) Physical exam & bedside assessments (practical, real-world)

1. Vital signs: fever, tachycardia, blood pressure elevation—common but nonspecific signs of early rejection or inflammation. Frontiers Publishing Partnerships

2. Focused graft exam: tenderness, swelling, or pain at the graft site (kidney) suggests active injury. Frontiers Publishing Partnerships

3. Fluid status check: sudden weight gain, edema, crackles—points to kidney/heart/lung graft dysfunction. Frontiers Publishing Partnerships

4. Urine output monitoring (kidney): oliguria/anuria is a red flag after transplantation. Frontiers Publishing Partnerships

5. Functional capacity (heart/lung): new breathlessness or exercise intolerance can flag graft injury needing urgent lab/imaging. Wiley Online Library

B) “Manual”/near-patient tests (simple, quick checks clinicians actually use)

6. Bedside urine dipstick (kidney): checks for blood/protein suggesting acute graft injury; quick but nonspecific. Frontiers Publishing Partnerships

7. Bedside ultrasound availability check: point-of-care ultrasound can rapidly screen for fluid around the graft; definitive Doppler is in Imaging below. Frontiers Publishing Partnerships

8. Blood pressure logs: persistent hypertension post-kidney transplant often parallels rejection risk and poor function. Frontiers Publishing Partnerships

9. Daily platelet count increments after transfusion: poor increment suggests HLA-mediated refractoriness. Frontiers

10. Simple metabolic panel (creatinine, electrolytes): quick declining function markers while immunology testing is arranged. Frontiers Publishing Partnerships

C) Laboratory & pathology (core of diagnosis and risk-stratification)

11. cPRA calculation: summarizes how many donors are incompatible based on the patient’s listed “unacceptable antigens.” Higher cPRA = fewer matches and higher sensitization. OPTN+1

12. HLA typing (recipient and prospective donor): defines the HLA “map” to interpret antibody results and decide unacceptable antigens. Frontiers Publishing Partnerships

13. Screening for anti-HLA (Luminex screening panel): initial screen for HLA class I/II antibodies. (Often followed by SAB.) PMC

14. Single-antigen bead (SAB) assay: pinpoints exact HLA targets and reports a signal (MFI). Very sensitive but inter-lab variability exists; MFI needs clinical context. Frontiers+1

15. Complement-binding assays (C1q or C3d on DSA): identify higher-risk, complement-activating antibodies linked to AMR and graft loss. PMC+2PMC+2

16. CDC crossmatch (with/without AHG): older cell-based test; specific but less sensitive, especially for class II. Still useful in some labs. PMC+1

17. Flow cytometric crossmatch (FCXM): more sensitive cell-based test; detects antibody binding to donor T/B cells with fluorescence. Wiley Online Library+1

18. Virtual crossmatch (VXM): computer comparison of donor HLA with the patient’s known antibodies to predict compatibility before an offer proceeds. PMC

19. Allograft biopsy with immunopathology: looks for microvascular injury and C4d deposition (a complement footprint) supporting AMR diagnosis; integrates with DSA results. Frontiers Publishing Partnerships

20. Donor-derived cell-free DNA (dd-cfDNA) and routine graft labs: rising dd-cfDNA and injury labs (e.g., creatinine for kidney) can support suspicion of rejection while immunology tests are processed. (Adjunct emerging marker used with DSA/biopsy.) Frontiers Publishing Partnerships

D) Electro-diagnostic tests (when the organ is heart or affects conduction)

• ECG in heart transplant recipients can show ischemia or arrhythmia if antibody injury compromises coronary microcirculation; it supports, but does not replace, immunology testing. Wiley Online Library

E) Imaging (to confirm perfusion and function)

• Doppler ultrasound (kidney, liver): evaluates arterial/venous flow and resistive indices; useful early after transplant.

• Echocardiography (heart): checks ventricular function and wall motion.

• CT or MR angiography / perfusion scans (organ-specific): assess vessel patency and graft perfusion when rejection or thrombosis is suspected. (Imaging sits alongside DSA and biopsy.) Frontiers Publishing Partnerships

Non-pharmacological treatments (therapies & other strategies)

(Each item includes a short description, purpose, and mechanism in simple English.)

1. Kidney-paired donation (KPD): If your living donor is incompatible, you “swap” with another pair so everyone gets a compatible kidney. Purpose: avoid high-risk antibody crossing. Mechanism: changes the donor, not your immune system. Lippincott Journals

2. Acceptable mismatch allocation (Eurotransplant model): Labs identify HLA targets you do not make antibodies against and prioritize organs carrying those “acceptable” antigens. Purpose: increase offers that are safe. Mechanism: smart matching reduces DSA. PMC+1

3. Deceased-donor priority for sensitized candidates: Some systems give extra points to highly sensitized patients so they get more offers. Purpose: cut waiting time. Mechanism: policy-level prioritization. Lippincott Journals

4. Plasmapheresis (PLEX): A machine removes antibody-rich plasma and returns cleaned blood. Purpose: lower antibody levels before/after transplant. Mechanism: physical removal of IgG. PMC

5. Immunoadsorption: A special column binds antibodies more selectively than PLEX. Purpose: deeper, faster antibody reduction. Mechanism: adsorptive capture of IgG/DSA. PMC

6. High-dose IVIG monotherapy (protocol-dependent): Although IVIG is a drug, many centers use it as a “procedural” infusion after PLEX; I list it here to show the common non-surgical bundle. Purpose: neutralize remaining antibodies and modulate immunity. Mechanism: anti-idiotype binding, Fc-receptor effects. PMC

7. Tighter blood transfusion stewardship: Avoid non-urgent transfusions to limit new sensitization while waiting. Purpose: prevent new HLA antibody formation. Mechanism: fewer foreign HLA exposures. Kidney International

8. Pregnancy counseling (future planning): Discuss sensitization risk with multiparous candidates. Purpose: informed choices; early listing. Mechanism: minimize additional immunizing events. Lippincott Journals

9. Virtual crossmatch (vXM) workflows: Use lab data to predict compatibility before offers. Purpose: reject unsafe offers and accept safe ones quickly. Mechanism: antibody specificity mapping. AJKD

10. Center-of-excellence referral: Complex desensitization is safest in experienced units. Purpose: improve outcomes. Mechanism: protocolized care, rapid rescue if AMR occurs. Oxford Academic

11. Education & shared decision-making: Clear discussion of risks and plan (e.g., rebound). Purpose: informed consent. Mechanism: align expectations, adherence. AMJ Transplant

12. Close post-transplant DSA monitoring: Scheduled antibody checks to catch rebound early. Purpose: detect AMR quickly. Mechanism: serial single-antigen bead testing. PMC

13. Biopsy-guided care if graft function dips: Prompt biopsy distinguishes AMR from other causes. Purpose: targeted treatment. Mechanism: histology + C4d + molecular assays. Oxford Academic

14. Nutrition & infection prevention basics: Good protein-energy balance and hygiene lower infection risk during intense immunomodulation. Purpose: safer recovery. Mechanism: support healing/immune competence. Lippincott Journals

15. Vaccination per transplant guidelines (pre-transplant): Finish non-live vaccines early. Purpose: reduce preventable infections when immunosuppressed. Mechanism: primed immunity before strong drugs. Lippincott Journals

16. Psychological support & adherence coaching: Complex schedules can be stressful. Purpose: improve adherence to treatments and monitoring. Mechanism: behavioral support. Lippincott Journals

17. Dialysis access optimization during desensitization: Reliable access for repeated PLEX/adsorption. Purpose: avoid delays/complications. Mechanism: stable vascular access. PMC

18. Infection control around apheresis: Catheter care and screening. Purpose: prevent line infections during repeated sessions. Mechanism: sterile technique, protocols. PMC

19. Multidisciplinary transplant board review: Nephrology, surgery, immunology, pathology decide timing and protocol. Purpose: individualized care. Mechanism: team consensus reduces error. Frontiers Publishing Partnerships

20. Long-term lifestyle plan (BP, diabetes, exercise): Protect the graft you worked hard to get. Purpose: extend graft life. Mechanism: reduce chronic injury risks. Lippincott Journals

---

Drug treatments

1. IVIG (intravenous immunoglobulin): Class: pooled IgG. Timing/Dose: often 2 g/kg total (e.g., 1–2 infusions), or 100 mg/kg after each PLEX—center-specific. Purpose: neutralize anti-HLA, modulate immune cells. Mechanism: anti-idiotype binding, Fc-receptor and complement effects. Side-effects: headache, thromboembolism (rare), hemolysis, aseptic meningitis. Evidence supports IVIG alone or with PLEX/rituximab. PMC

2. Rituximab: Class: anti-CD20 monoclonal antibody. Timing/Dose: commonly 375 mg/m² once (or 1–2 doses) pre-transplant. Purpose: deplete B cells that make antibodies. Mechanism: ADCC/complement lysis of CD20+ B cells. Side-effects: infusion reactions, infections, late hypogammaglobulinemia. Evidence quality is mixed for desensitization; widely used in protocols. PMC+1

3. Bortezomib: Class: proteasome inhibitor. Timing/Dose: e.g., 1.3 mg/m² days 1,4,8,11 (regimens vary). Purpose: target plasma cells that secrete antibodies. Mechanism: proteasome blockade → plasma-cell apoptosis. Side-effects: neuropathy, cytopenias, GI upset. Helps in some refractory AMR; evidence still evolving. JHLT Online+1

4. Carfilzomib: Class: second-gen proteasome inhibitor. Timing/Dose: center-specific pulses. Purpose/mechanism: like bortezomib, sometimes better tolerated neuropathy-wise. Side-effects: cardiac events, cytopenias; close monitoring needed. Data growing but limited. Oxford Academic

5. Tocilizumab: Class: IL-6 receptor blocker. Timing/Dose: monthly IV or SC courses in refractory AMR/desensitization. Purpose: dampen plasma-cell help and inflammation. Mechanism: blocks IL-6 signaling. Side-effects: infection risk, liver enzymes, GI perforation rare. Evidence promising but not definitive. Oxford Academic

6. Daratumumab: Class: anti-CD38 monoclonal antibody. Timing/Dose: weekly to monthly courses (myeloma-style, adapted). Purpose: deplete plasma cells and NK cells. Mechanism: ADCC/complement against CD38+ cells. Side-effects: infusion reactions, cytopenias, infections. Emerging option for difficult cases. Oxford Academic

7. Imlifidase (IdeS, Idefirix): Class: IgG-cleaving enzyme. Timing/Dose: two IV doses (0.25 mg/kg ~6–24 hours apart) shortly before transplant in selected highly sensitized patients. Purpose: rapidly cut IgG (including DSA) to allow a negative crossmatch at time of transplant. Mechanism: cleaves human IgG into fragments. Side-effects: DSA rebound risk, infections; requires strong background immunosuppression. Five-year outcomes show good graft survival when used in protocols. Oxford Academic+2AMJ Transplant+2

8. Eculizumab: Class: C5 complement inhibitor. Timing/Dose: peri-transplant or for AMR rescue (center-specific). Purpose: blunt complement-mediated graft injury. Mechanism: blocks MAC formation. Side-effects: meningococcal infection risk (vaccinate), headache. Data mixed; costly; select use. Oxford Academic

9. C1 esterase inhibitor (C1-INH): Class: complement regulator concentrate. Timing/Dose: adjunctive doses in AMR or high-risk desensitization. Purpose: reduce early complement injury. Mechanism: inhibits C1r/C1s. Side-effects: rare thrombosis, hypersensitivity. Evidence small but growing. Oxford Academic

10. Belatacept: Class: costimulation blocker (CTLA4-Ig). Timing/Dose: maintenance alternative to calcineurin inhibitors; sometimes in protocols post-imlifidase. Purpose: reduce T-cell help for antibody responses; preserve kidney function. Mechanism: blocks CD80/86–CD28 signaling. Side-effects: PTLD risk in EBV-naïve, infections. Select centers use it for HLA-incompatible strategies. Oxford Academic

11. High-dose steroids (methylprednisolone): Class: glucocorticoid. Timing/Dose: pulses for AMR or peri-transplant. Purpose: broad anti-inflammatory effect. Mechanism: gene transcription changes. Side-effects: glucose rise, mood, infection, bone loss. Standard supportive role. Oxford Academic

12. Tacrolimus (or cyclosporine): Class: calcineurin inhibitor. Timing/Dose: maintenance immunosuppression post-transplant. Purpose: suppress T-cell activation to limit help for antibody production. Mechanism: blocks IL-2 transcription. Side-effects: kidney toxicity (cyclosporine/tacrolimus), tremor, diabetes risk. Foundation of regimens. Lippincott Journals

13. Mycophenolate mofetil (or mycophenolic acid): Class: antiproliferative. Timing/Dose: maintenance. Purpose: reduce B/T-cell proliferation. Mechanism: IMPDH inhibition. Side-effects: GI upset, cytopenias, infection risk. Core maintenance drug. Lippincott Journals

14. mTOR inhibitors (sirolimus/everolimus): Class: mTOR blockade. Timing/Dose: alternative/adjunct maintenance. Purpose: immunosuppression with CNI sparing in some cases. Mechanism: cell-cycle effects. Side-effects: mouth ulcers, lipids, wound-healing. Selected use. Lippincott Journals

15. Cyclophosphamide (rare today): Class: alkylator. Timing/Dose: occasionally for rescue in severe refractory cases. Purpose: broad B-cell/plasma-cell suppression. Mechanism: DNA alkylation. Side-effects: marrow suppression, hemorrhagic cystitis. Historical/rare modern role. Oxford Academic

16. Azathioprine (historical alternative): Class: antimetabolite. Timing/Dose: maintenance alternative to mycophenolate. Purpose/Mechanism: purine analog → lymphocyte suppression. Side-effects: cytopenias, hepatotoxicity. Less used now. Lippincott Journals

17. Proteasome-inhibitor combos (e.g., bortezomib + rituximab + PLEX/IVIG): Class: combination approach. Timing/Dose: protocolized courses. Purpose: hit plasma cells and B-cell precursors. Mechanism: multi-hit antibody reduction. Side-effects: combined toxicities; careful selection. JHLT Online

18. Anti-IL-6/IL-6R sequences (tocilizumab/sarilumab in studies): Class: cytokine blockers. Timing/Dose: monthly courses in refractory cases. Purpose/Mechanism: reduce plasma-cell support and inflammation. Side-effects: infections, labs. Evidence not definitive. Oxford Academic

19. Anti-CD38 sequences (daratumumab/isatuximab in reports): Class: plasma-cell depleters. Timing/Dose: adapted from myeloma regimens. Purpose/Mechanism: reduce long-lived antibody producers. Side-effects: infusion reactions, cytopenias. Emerging data. Oxford Academic

20. Imlifidase-anchored, time-critical protocols (with rapid induction + maintenance): Class: enzyme + immunosuppression bundles. Timing: 0–24 h pre-transplant plus tailored maintenance to blunt rebound. Purpose/Mechanism: clear IgG fast then prevent return. Side-effects: as above; careful DSA monitoring needed. Five-year follow-up supports viability when used by experienced centers. PMC+1

Important: Protocols vary by center and patient. Several agents above have limited or mixed evidence for desensitization/AMR (high-quality randomized data are scarce), so teams balance potential benefit vs risk carefully. Oxford Academic

---

Dietary molecular supplement

(There is no proven supplement that safely “erases” anti-HLA antibodies. The points below are supportive care only, aligned with transplant-candidate nutrition guidance. Always clear supplements with your team because many interact with immunosuppressants.)

1. Adequate protein (food first): Supports healing and immune function during apheresis and after surgery; dietitian sets grams/day. Mechanism: maintains lean mass, antibody-independent recovery. Lippincott Journals

2. Vitamin D (if deficient): Correct deficiency per labs; helps bone/immune balance. Mechanism: modulates innate/adaptive immunity; no DSA deletion. Lippincott Journals

3. Iron (if iron-deficient): Treat documented deficiency to avoid transfusions that can raise sensitization. Mechanism: fixes anemia, may reduce transfusion need. Kidney International

4. Folic acid/B-vitamins (per labs): Correct deficiencies; supports blood cell production under immunosuppression. Mechanism: co-factors, not anti-DSA. Lippincott Journals

5. Omega-3 from food (fish) or approved capsules: General cardiometabolic support; avoid high, unmonitored doses. Mechanism: mild anti-inflammatory; no proven DSA effect. Lippincott Journals

6. Probiotics/fermented foods (only if team approves pre-transplant): Gut health; avoid after transplant unless cleared (infection risk in immunosuppression). Mechanism: microbiome support, not DSA modulation. Lippincott Journals

7. Iodized salt/thyroid-adequate diet: Support metabolic stability; avoid extreme iodine supplements. Mechanism: supports baseline physiology. Lippincott Journals

8. Phosphate/potassium control (in dialysis): Dietitian-guided binders/diet to avoid complications that delay desensitization/transplant. Mechanism: metabolic optimization. Lippincott Journals

9. Avoid unproven “immune boosters” (echinacea, high-dose herbs): They may stimulate immunity or interact with drugs and raise rejection risk. Mechanism: cytochrome interactions/immune activation. Lippincott Journals

10. Caffeine moderation & hydration: Prevent headaches and cramps around PLEX; follow fluid limits in dialysis. Mechanism: symptom management, not antibody change. PMC

---

Immunity booster / regenerative / stem-cell drug

There is no safe “booster” to raise immunity while also lowering anti-HLA antibodies. In transplant care, we intentionally suppress specific parts of the immune system to protect the graft, then prevent infection with vaccines and antimicrobial strategies. Any product advertised as an “immune booster” can be harmful here. Lippincott Journals

1. Vaccines (pre-transplant): “Boost” protective immunity before heavy immunosuppression (non-live vaccines only). Doses per national schedules. Function: reduce infection risk later. Mechanism: antigen-specific memory. Lippincott Journals

2. IVIG (supportive aspect): Besides desensitization, IVIG can support humoral immunity when IgG is low. Function: passive antibodies. Mechanism: pooled IgG. PMC

3. G-CSF (when neutrophils are very low): Not a desensitizer; sometimes used to treat severe neutropenia during intense therapy. Function: raise neutrophil count. Mechanism: stimulates marrow. Lippincott Journals

4. No role for “stem-cell boosters” or retail “regenerative” pills: These are not proven for HLA antibodies and may be unsafe. Function/Mechanism: none supported for this indication. Oxford Academic

5. Nutritional repletion (dietitian-led): Supports tissue repair after surgery. Function: not immune “boost,” but healing. Mechanism: adequate macro-/micronutrients. Lippincott Journals

6. Exercise rehabilitation: Post-transplant, graded activity safely improves strength and function. Function: better recovery. Mechanism: conditioning, not DSA change. Lippincott Journals

---

Surgeries/procedures

1. Kidney transplantation after desensitization: The goal is to achieve a safe crossmatch and proceed to surgery. Why: offer survival and quality of life benefits compared with remaining on dialysis in many patients. ScienceDirect

2. Catheter placement for apheresis (PLEX/immunoadsorption): A reliable central line may be needed for repeated sessions. Why: safe, efficient antibody removal. PMC

3. Allograft biopsy (post-transplant): Core needle biopsy is a procedure, not an operation, but it’s critical. Why: confirm/rule out AMR and guide therapy. Oxford Academic

4. Transplant nephrectomy (rare, for non-functioning graft with severe rejection): Why: prevent ongoing inflammation/infection risk if the graft cannot be salvaged. Oxford Academic

5. Splenectomy (historical/rare today): Used occasionally in the past to lower antibody production; now largely replaced by modern medical protocols. Why: legacy option when other measures fail. Oxford Academic

---

Preventions

1. Avoid non-urgent blood transfusions while waiting (treat iron deficiency first). Kidney International

2. Use kidney-paired donation or acceptable mismatch routes early. PMC

3. Finish non-live vaccines pre-transplant. Lippincott Journals

4. Adhere to all desensitization sessions exactly as planned. PMC

5. Keep good catheter hygiene during PLEX/adsorption. PMC

6. Attend all DSA blood tests after transplant to catch rebound early. PMC

7. Control blood pressure, diabetes, and lipids to protect the graft. Lippincott Journals

8. Tell your team about any infections or new medicines immediately. Lippincott Journals

9. Use one transplant center’s protocol whenever possible (avoid fragmented care). Frontiers Publishing Partnerships

10. Rely on proven therapies—avoid “immune boosters” and unregulated supplements. Oxford Academic

---

When to see doctors urgently

• Before transplant: fever, chills, line redness, trouble breathing, chest pain, severe swelling, or missed PLEX/adsorption sessions—call the team now. Why: infections and delays can derail desensitization. PMC

• After transplant: sudden drop in urine, rising creatinine, fever, pain over the transplant, new swelling, shortness of breath, severe diarrhea/vomiting, or any new rash after infusions—seek urgent care. Why: could be AMR, infection, or drug effects; early action saves the graft. Oxford Academic

---

What to eat & what to avoid

Eat (as cleared by your team): balanced meals with enough protein (eggs, fish, poultry, legumes), whole grains, fruits/vegetables safe for your kidney stage, and healthy fats (olive oil, nuts in moderation). If you’re on dialysis, follow your potassium, phosphate, and sodium limits with your dietitian. Why: supports healing and avoids emergency transfusions or metabolic problems that could delay surgery. Lippincott Journals+1

Avoid: raw/undercooked meats or unpasteurized foods near the time of transplant; high-dose or unapproved herbal “immune boosters”; over-the-counter NSAIDs unless your team says okay; and excess salt/sugar. Why: infection risk, drug interactions, and blood-pressure spikes can harm the graft. Lippincott Journals

---

Frequently asked questions

1. Can very high anti-HLA antibodies go away?
   They can fall with time and careful treatment, but may rebound; strict follow-up is key. PMC

2. Is transplant still possible when cPRA is >99%?
   Yes. With acceptable mismatch, paired exchange, and tools like imlifidase in selected cases, many patients receive kidneys. PMC+1

3. What is the biggest danger if I “cross” my antibodies?
   Antibody-mediated rejection, which can damage the kidney fast. Lippincott Journals

4. Does plasmapheresis cure the problem?
   It lowers antibodies quickly, but they can rebound; maintenance drugs help keep them down. PMC

5. Is IVIG safe?
   Usually, yes, but headaches and rare clots can happen; teams screen carefully. PMC

6. Is rituximab proven?
   It’s widely used, but high-quality randomized proof for desensitization is limited; decisions are individualized. Oxford Academic

7. What is imlifidase?
   An enzyme that cuts IgG quickly to make the crossmatch negative for a short window before transplant. Oxford Academic

8. Will my antibodies come back after imlifidase?
   They often rebound, so centers add strong immunosuppression and close DSA monitoring. AMJ Transplant+1

9. Do complement drugs like eculizumab help?
   They can help in selected cases but are expensive, require vaccination, and evidence is mixed. Oxford Academic

10. Can diet or supplements remove HLA antibodies?
    No. Diet supports health, but only medical/procedural therapies change DSA. Lippincott Journals

11. Is waiting on dialysis safer than a risky transplant?
    For some, a compatible transplant brings better survival and life quality; teams compare your personal risks vs benefits. ScienceDirect

12. What is “virtual crossmatch”?
    A lab prediction based on your antibody list and a donor’s HLA to decide if the match is safe before saying “yes.” AJKD

13. Are class II antibodies worse?
    They’re often tougher to lower and linked to chronic injury; teams pay close attention to them. PMC

14. What happens if I get AMR?
    Doctors combine PLEX/adsorption, IVIG, steroids, and sometimes proteasome or IL-6 pathway drugs; biopsy guides care. Oxford Academic

15. Will I need lifelong monitoring?
    Yes—labs, DSA checks as indicated, medicines every day, and healthy living to protect your kidney. Lippincott Journals

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 19, 2025.